Is cardiometabolic risk improved by weight-loss drugs?
Astrup
Arne
A
Department of Human Nutrition, Faculty of Life Sciences, University of Copenhagen, DK-1958 Frederiksberg, Copenhagen, Denmark. ast@life.ku.dk
D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016642:Bupropion / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D004359:Drug Therapy, Combination; D006801:Humans; D009271:Naltrexone / Q000008:administration & dosage*; D009765:Obesity / Q000150:complications / Q000188:drug therapy*; D012307:Risk Factors
D019440:Anti-Obesity Agents; D016642:Bupropion; D009271:Naltrexone